Serine/threonine-protein kinase ATR · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Serine/threonine-protein kinase ATR shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q13535. Start with non-small cell lung carcinoma, then reuse UniProt Q13535 as the stable protein anchor across project notes and exports.
Start with non-small cell lung carcinoma, then reuse UniProt Q13535 as the stable protein anchor across project notes and exports.
Serine/threonine-protein kinase ATR shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include BERZOSERTIB, CERALASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySerine/threonine-protein kinase ATR
Review this target as Serine/threonine-protein kinase ATR, mapped to UniProt Q13535. Sequence length is 2644 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase ATR as ChEMBL target CHEMBL5024, mapped to UniProt Q13535. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Serine/threonine-protein kinase ATR is the right protein anchor across sources, using UniProt Q13535 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why non-small cell lung carcinoma is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Serine/threonine-protein kinase ATR |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q13535 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Serine/threonine-protein kinase ATR |
| UniProt Accession | Q13535 |
| Component Type | Protein |
| Sequence Length | 2644 aa |
Serine/threonine-protein kinase ATR
Review this target as Serine/threonine-protein kinase ATR, mapped to UniProt Q13535. Sequence length is 2644 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Serine/threonine-protein kinase ATR shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.
Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include BERZOSERTIB, CERALASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4285417 | 10.22 | Ki | 0.06 | Clinical |
| CHEMBL3355476 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL4444602 | 9.85 | Ki | 0.14 | Preclinical |
| CHEMBL3989870 | 9.83 | Ki | 0.148 | Clinical |
| CHEMBL4650286 | 9.82 | IC50 | 0.15 | Preclinical |
| CHEMBL3989870 | 9.77 | IC50 | 0.17 | Clinical |
| CHEMBL3355474 | 9.7 | IC50 | 0.2 | Preclinical |
| CHEMBL4533440 | 9.68 | Ki | 0.21 | Preclinical |
| CHEMBL4443525 | 9.57 | Ki | 0.27 | Preclinical |
| CHEMBL3355072 | 9.52 | IC50 | 0.3 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 75 | 1,754 | 6.5 |
| cell-based format | 66 | 213 | 6.6 |
| subcellular format | 15 | 1 | 8.3 |
| assay format | 3 | 19 | 6.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 2 | 0 | — |